奇朗配方通过准SCF/c-kit信号通路来缓解便秘:网络药理学和实验验证的综合研究
Jiacheng Li1,2, Yugang Fu1,2, Yanping Wang1,2
1Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
Heliyon
|June 6, 2024
概括
奇朗配方 (QLF) 通过促进肠道光滑肌肉细胞的增殖,有效治疗便秘. 它针对SCF/c-Kit通路,改善肠道运动性并恢复神经递质平衡,以改善生活质量.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 便秘是一种普遍存在的功能性胃肠道疾病,影响患者的生活质量.
- 奇朗配方 (QLF) 在缓解便秘方面表现有前途,但其潜在的治疗机制需要阐明.
研究的目的:
- 研究朗配方 (QLF) 改善便秘的分子机制.
- 在便秘的背景下,确定QLF调节的关键目标和途径.
主要方法:
- 通过UPLC-MS/MS分析QLF,从多个数据库中识别目标,并构建网络药理学.
- 在体内研究包括H&E染色,传输电子显微镜 (TEM),ELISA,西部斑点,并在鼠标便秘模型中的免疫光.
- 分子对接以评估QLF活性成分与已识别的标的结合亲和力.
主要成果:
- 确定了89个与便秘相关的QLF目标,其中c-Kit是关键目标.
- QLF的使用显著改善了肠道排便频率,便水分和肠道通行.
- QLF治疗恢复了神经递质水平,减轻了结肠损伤,并促进了Cajal (ICC) 间歇细胞的增殖和c-Kit表达.
结论:
- 通过准SCF/c-Kit信号通路,QLF促进了ICC的增殖,并调节了肠道运动.
- 这些发现为QLF在治疗便秘的有效性提供了机制基础.
更多相关视频
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
157
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
157
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
203
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
203
Drugs Affecting GI Tract Motility: Other Laxatives
196
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
196
Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
247
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
247


